Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.63 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.63 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | FABP3 | P05413 | 2/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7927718 | 0.89 | TTR (0.52) | GABRA1GABRB2GABRB1CA1CA2 | |
| SCHEMBL94533 | 0.84 | GABRA1 (0.77) | GABRA1GABRB2GABRB1CA1CA2 | |
| Ammonia Solution, Strong SCHEMBL28098766 | 0.81 | GABRA1 (0.74) | GABRA1GABRB2GABRB1CA1CA2 | |
| SCHEMBL18778629 | 0.80 | PTGS1 (0.44) | GABRA1GABRB2GABRB1CA1CA2 | |
| SCHEMBL7927726 | 0.80 | GABRA1 (0.78) | GABRA1GABRB2GABRB1CA1CA2 | |
| SCHEMBL1617739 | 0.77 | GABRA1 (1.00) | GABRA1GABRB2GABRB1CA1CA2 | |
| SCHEMBL15064751 | 0.77 | GABRA1 (0.68) | GABRA1GABRB2GABRB1CA1CA2 | |
| SCHEMBL817922 | 0.77 | GABRA1 (0.72) | GABRA1GABRB2GABRB1CA1CA2 | |
| SCHEMBL6943696 | 0.76 | GABRA1 (0.65) | GABRA1GABRB2GABRB1CA1CA2 | |
| SCHEMBL30467045 | 0.76 | GABRA1 (0.65) | GABRA1GABRB2GABRB1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1373240-B1 | RETINOID X RECEPTOR MODULATORS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040167160-A1 | Retinoid x receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| EP-1373240-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002071827-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167160-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | GABRA1 344/4885GABRB2 816/4885GABRB1 640/4885 |
| US-20080090860-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | GABRA1 337/4885GABRB2 884/4885GABRB1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.